Merck (MRK) also had above average risk, with thei
Post# of 157616
(Total Views: 719)
Posted On: 09/12/2025 5:51:56 PM
Merck (MRK) also had above average risk, with their at-risk products making up 56% of 2024 revenue...financial situation in 2025 is exacerbated exponentially.
.The disease areas with the most significant number of FDA approvals in 1St half
of 2024;
Oncology with:29 approvals (34.94%)
Autoimmune/Inflammation:11 approvals (13.25%)
Looking for 2025 Stats..so far looks like mixed bag.
.The disease areas with the most significant number of FDA approvals in 1St half
of 2024;
Oncology with:29 approvals (34.94%)
Autoimmune/Inflammation:11 approvals (13.25%)
Looking for 2025 Stats..so far looks like mixed bag.
(3)
(0)